Pharmaceutical

Adcendo and Multitude ink ADC deal potentially worth $1bn

Adcendo will acquire ex-China global rights for Multitude’s tissue factor-targeting ADC.

Aug 21, 2024 - 04:00
Adcendo and Multitude ink ADC deal potentially worth $1bn
Adcendo will acquire ex-China global rights for Multitude’s tissue factor-targeting ADC.
Read the original article

Tags:

Previous Article

Researchers teaching artificial intelligence about frustration in protein folding

Next Article

J&Js Rybrevant plus Lazcluze combination gets FDA approval in NSCLC

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Moderna concludes construction at new mRNA vaccine facility in Canada

Moderna concludes construction at new mRNA vaccine faci...

Feb 26, 2024

STAT+: Pharmalittle: German regulator eyes Ozempic export ban amid shortages; NIH-funded clinical trials lagging pharma’s in enrollment

STAT+: Pharmalittle: German regulator eyes Ozempic expo...

Nov 15, 2023

FDA approves Sun Pharma’s JAK inhibitor for alopecia

FDA approves Sun Pharma’s JAK inhibitor for alopecia

Jul 28, 2024